Vitamin K2 has long been recognised as an important nutrient for bone health and adequate Vitamin K2 intake has also been shown to positively influence the cardiovascular system. Yet populations are deficient of this vital nutrient due to diet and commonly prescribed medications. MenaQ7 from NattoPharma is the only Vitamin K2 as MK-7 shown in groundbreaking clinical studies to positively impact both bone and heart health, leading to it being the only Vitamin K2 as MK-7 patented for cardiovascular health.*
Most people associate Vitamin K with coagulation, however, Vitamin K—specifically Vitamin K2—has earned a strong reputation as an effective bone and cardiovascular support nutrient due to a substantial body of recent clinical evidence.
Both bone and cardiovascular health are dictated by how the body utilises calcium. Ideally the body will bind calcium to the bone mineral matrix, making stronger, denser bones. But if left unattended, calcium does not make it to our bones. Rather, it will deposit in arteries, blood vessels and soft tissues, increasing risks for developing cardiovascular diseases.
Enter Vitamin K2: by activating proteins already present in the body—Osteocalcin and Matrix Gla Protein (MGP), respectively—K2 binds calcium to the bones, while stopping it from depositing in arteries and soft tissues.
Unfortunately, Western populations have insufficient intake of Vitamin K2 from their regular diets. Further, a recent review highlighted that statins, the most prescribed cholesterol medication, actually inhibit the synthesis of K2, limiting its ability to activate MGP.
Like most nutritional ingredients, there are many varieties offered by different suppliers in the market and Vitamin K2 is no exception. However, one Vitamin K2 as MK-7 (MenaQ7 from NattoPharma) has been the source material for the clinical studies discovering and confirming the health benefits of Vitamin K2, including the studies done with Vitamin D3 and the groundbreaking bone and cardiovascular studies cited by all K2 suppliers.
A three year study of 244 healthy post-menopausal women taking 180 microgram dose of MenaQ7 Vitamin K2 as MK-7 daily yielded unprecedented results:
These findings are significant because this is the first time any form of vitamin K has shown these benefits. This is also true of other therapies to date, no compound has ever before demonstrated these benefits and the only Vitamin K2 as MK-7 to demonstrate them is MenaQ7 from NattoPharma.
Vitamin K2 as MK-7 is now known as an essential nutrient for all life’s stages because:
These ongoing efforts open new avenues for manufacturers, creating true potential for products.
In addition to being the best clinically validated K2 on the market, MenaQ7 offers the ONLY comprehensive Vitamin K2 portfolio, giving manufacturers the option of using natural (either soy and chickpea sourced) or natural-identical synthetic options. And these varieties come in an array of solubilities so that MenaQ7 can be incorporated into almost any application imaginable.
Contact NattoPharma today to learn more about incorporating the technology in your formulation to ensure the most robust delivery of MenaQ7 Vitamin K2 as MK-7.Reference:
1. Knapen MHJ, Drummen NE, Smit E, Vermeer C, Theuwissen E. Osteoporos Int. (Sept 2013). 24(9): 2499-2507.
2. Knapen MH et al, Braam LAJL, Drummen NE, Bekers O, Hoeks APG, Vermeer C. Thrombosis and Haemostasis. 2015 113 5: 1135-1144.
*NattoPharma ASA has the exclusive use of a Vitamin K2 patent portfolio originating with VitaK, world experts in vitamin K, at Maastricht University. The company continues to develop this patent portfolio, with new and expanding claims regarding the benefits of vitamin K, and especially vitamin K2. To that end, MenaQ7 is has six patents granted and pending in USA, Canada, 15 European countries, New Zealand, Australia, Japan, India, Korea, South Korea, and China.